[go: up one dir, main page]

WO1992001049A3 - Antigene de surface de cellule cd53 et son utilisation - Google Patents

Antigene de surface de cellule cd53 et son utilisation Download PDF

Info

Publication number
WO1992001049A3
WO1992001049A3 PCT/US1991/004986 US9104986W WO9201049A3 WO 1992001049 A3 WO1992001049 A3 WO 1992001049A3 US 9104986 W US9104986 W US 9104986W WO 9201049 A3 WO9201049 A3 WO 9201049A3
Authority
WO
WIPO (PCT)
Prior art keywords
cell surface
cloning
mammalian
highly efficient
surface antigens
Prior art date
Application number
PCT/US1991/004986
Other languages
English (en)
Other versions
WO1992001049A2 (fr
Inventor
Brian Seed
Alejandro Aruffo
Martine Amiot
Original Assignee
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Hospital Corp filed Critical Gen Hospital Corp
Priority to AU85286/91A priority Critical patent/AU658370B2/en
Priority to CA002087272A priority patent/CA2087272C/fr
Priority to JP3515602A priority patent/JPH06504186A/ja
Priority to KR1019930700092A priority patent/KR100206524B1/ko
Publication of WO1992001049A2 publication Critical patent/WO1992001049A2/fr
Publication of WO1992001049A3 publication Critical patent/WO1992001049A3/fr
Priority to KR1019997001739A priority patent/KR100229113B1/ko
Priority to KR1019997001740A priority patent/KR100229114B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

On a découvert un procédé simple et hautement efficace de clonage d'ADNs complémentaires à partir de banques d'expression mammifère basées sur l'expression transitoire dans des cellules hôtes mammifères. L'invention concerne également de nouveaux vecteurs d'expression permettant l'élaboration hautement efficace de banques d'ADNs complémentaires mammifères. Le procédé de clonage de l'invention ayant été utilisé pour cloner des gènes destinés à des antigènes de surface de cellules de lymphocytes humains, présente une application générale dans le clonage de gènes. On a purifié des antigènes de surface de cellules clonées selon l'invention, et on a déterminé les séquences de nucléotides et d'acides aminés. Ces antigènes présentent une utilité diagnostique et thérapeutique dans des infections d'origine immunitaire chez des mammifères, y compris chez l'homme.
PCT/US1991/004986 1990-07-13 1991-07-15 Antigene de surface de cellule cd53 et son utilisation WO1992001049A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU85286/91A AU658370B2 (en) 1990-07-13 1991-07-15 CD53 cell surface antigen and use thereof
CA002087272A CA2087272C (fr) 1990-07-13 1991-07-15 Antigene de surface des lymphocytes cd53 et son utilisation
JP3515602A JPH06504186A (ja) 1990-07-13 1991-07-15 Ｃｄ５３細胞表面抗原とその使用
KR1019930700092A KR100206524B1 (ko) 1990-07-13 1991-07-15 씨디 53 세포 표면 항원 및 그를 암호화하는 재조합 디엔에이
KR1019997001739A KR100229113B1 (ko) 1990-07-13 1999-03-02 티엘아이에스에이 세포 표면 항원 및 그를 암호화하는 재조합 디엔에이
KR1019997001740A KR100229114B1 (ko) 1990-07-13 1999-03-02 씨디27세포 표면 항원 및 그를 암호화하는 재조합 디엔에이

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55375990A 1990-07-13 1990-07-13
US553,759 1990-07-13

Publications (2)

Publication Number Publication Date
WO1992001049A2 WO1992001049A2 (fr) 1992-01-23
WO1992001049A3 true WO1992001049A3 (fr) 1993-09-30

Family

ID=24210641

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1991/004986 WO1992001049A2 (fr) 1990-07-13 1991-07-15 Antigene de surface de cellule cd53 et son utilisation

Country Status (8)

Country Link
EP (1) EP0551301A1 (fr)
JP (3) JPH06504186A (fr)
KR (1) KR100206524B1 (fr)
AU (1) AU658370B2 (fr)
CA (1) CA2087272C (fr)
IE (1) IE912466A1 (fr)
PT (1) PT98326B (fr)
WO (1) WO1992001049A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7132395B1 (en) 1988-09-01 2006-11-07 Bayer Pharmaceuticals Corporation Antiviral methods using human rhinovirus receptor (ICAM-1)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6107461A (en) * 1990-07-20 2000-08-22 Bayer Corporation Multimeric forms of human rhinovirus receptor and fragments thereof, and method of use
US6130202A (en) * 1990-07-20 2000-10-10 Bayer Corporation Antiviral methods
US5316920A (en) * 1992-04-17 1994-05-31 Dana-Faber Cancer Institute, Inc. Lymphocyte activation antigen HB15, a member of the immunoglobulin superfamily
CA2134655A1 (fr) * 1992-04-30 1993-11-11 Russell J. Howard Modulation des interactions de la thrombospondine-cd36
JP2800850B2 (ja) * 1992-07-21 1998-09-21 アイシス・イノベーション・リミテッド 新生物形成の検出方法
WO1996033217A1 (fr) * 1995-04-19 1996-10-24 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Proteine d'adhesion de cellules, agent immunosuppresseur contenant cette proteine et agent immunosuppresseur renfermant des cellules ainsi induites
US5990299A (en) * 1995-08-14 1999-11-23 Icn Pharmaceuticals, Inc. Control of CD44 gene expression for therapeutic use
AU7739696A (en) * 1995-11-30 1997-06-19 Schering Corporation Dnam, an nk antigen and adhesion molecule of the immunoglobulin superfamily
US5863735A (en) * 1997-02-24 1999-01-26 Incyte Pharmaceuticals, Inc. Human transmembrane 4 superfamily protein
US5854022A (en) * 1997-05-13 1998-12-29 Incyte Pharmaceuticals, Inc. Polynucleotides encoding a CD53-like transmembrane protein
US6486299B1 (en) * 1998-09-28 2002-11-26 Curagen Corporation Genes and proteins predictive and therapeutic for stroke, hypertension, diabetes and obesity
EP1006183A1 (fr) * 1998-12-03 2000-06-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Récepteurs Fc recombinantes et solubles
JP4198990B2 (ja) 2000-10-18 2008-12-17 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 造血細胞のｅ−セレクチン／ｌ−セレクチンリガンドポリペプチドおよびその使用法
WO2005044075A2 (fr) * 2003-09-19 2005-05-19 Diadexus, Inc. Compositions, variantes d'epissures, et procedes se rapportant a des genes et proteines specifiques du sein
SG10201912554TA (en) 2005-03-23 2020-02-27 Genmab As Antibodies against cd38 for treatment of multiple myeloma
AU2007254777B2 (en) 2006-06-02 2014-02-20 Robert Sackstein Compositions and methods for modifying cell surface glycans
EP3753576A1 (fr) 2006-09-26 2020-12-23 Genmab A/S Traitement combine de tumeurs exprimant la cd38
EP2090320A1 (fr) * 2008-02-15 2009-08-19 Helmholtz-Zentrum für Infektionsforschung GmbH Ligands du marqueur CD27 de surface de cellule tueuse naturelle (NK) et ses utilisations thérapeutiques
CN103154034B (zh) 2010-04-13 2016-06-08 塞尔德克斯医疗公司 结合人cd27的抗体及其用途
DK2580243T3 (da) 2010-06-09 2020-01-13 Genmab As Antibodies against human cd38
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
ES2890669T3 (es) 2014-09-09 2022-01-21 Janssen Biotech Inc Terapias de combinación con anticuerpos anti-CD38
SG11201704390PA (en) 2014-12-04 2017-06-29 Janssen Biotech Inc Anti-cd38 antibodies for treatment of acute myeloid leukemia
DK3597663T3 (da) 2014-12-08 2022-06-27 Us Health Kimære antigenreceptorer af anti-cd70
KR102602754B1 (ko) 2015-05-20 2023-11-14 얀센 바이오테크 인코포레이티드 경쇄 아밀로이드증 및 다른 cd38-양성 혈액학적 악성종양을 치료하기 위한 항-cd38 항체
CN107708734B (zh) 2015-06-22 2022-01-11 詹森生物科技公司 用抗cd38抗体和生存素抑制剂联合治疗血红素恶性肿瘤
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
ES2862425T3 (es) 2015-11-03 2021-10-07 Janssen Biotech Inc Formulaciones subcutáneas de anticuerpos anti-CD38 y sus usos
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
MA50514A (fr) 2017-10-31 2020-09-09 Janssen Biotech Inc Méthodes de traitement du myélome multiple à haut risque
SG11202010011RA (en) 2018-04-17 2020-11-27 Celldex Therapeutics Inc Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs
AU2020304415A1 (en) * 2019-06-27 2022-02-17 Verseau Therapeutics, Inc. Anti-CD53 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof
KR20230161571A (ko) 2022-05-18 2023-11-28 엘지전자 주식회사 옷걸이 및 옷걸이를 구비하는 의류처리장치
KR20230161570A (ko) 2022-05-18 2023-11-28 엘지전자 주식회사 옷걸이 및 옷걸이를 구비하는 의류처리장치
KR20230161572A (ko) 2022-05-18 2023-11-28 엘지전자 주식회사 옷걸이 및 옷걸이를 구비하는 의류처리장치
KR20230161569A (ko) 2022-05-18 2023-11-28 엘지전자 주식회사 옷걸이 및 옷걸이를 구비하는 의류처리장치
KR20230161568A (ko) 2022-05-18 2023-11-28 엘지전자 주식회사 옷걸이 및 옷걸이를 구비하는 의류처리장치

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0330191A2 (fr) * 1988-02-25 1989-08-30 The General Hospital Corporation ADN encodant CD40

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0330191A2 (fr) * 1988-02-25 1989-08-30 The General Hospital Corporation ADN encodant CD40

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
IMMUNOGENETICS, Vol. 32, No. 4, October 1990, SPRINGER INTERNATIONAL, pages 281-285, ANGELISOVA P. et al., "The Human Leukocyte Surface Antigen CD53 is a Protein Structurally Similar to the CD37 and MRC OX-44 Antigens". *
JOURNAL OF IMMUNOLOGY, Vol. 145, No. 12, 15 December 1990, Baltimore, US, pages 4322-4325, AMIOT M. et al., "Identification and Analysis of cDNA Clones Encoding CD53 -A Pan Leukocyte Antigen Related to Membrane Transport Proteins". *
KNAPP W. et al., "Leucocyte Typing IV -White Cell Differentiation Antigens-", 1989, OXFORD UNIVERSITY PRESS, WALTON STREET, OXFORD, GB, "N13 Cluster Report : CD53", pages 674-678. *
KNAPP W. et al., "Leucocyte Typing IV -White Cell Differentiation Antigens-", 1989, OXFORD UNIVERSITY PRESS, WALTON STREET, OXFORD, GB, "N13.1 Reactivity of the Non Lineage/NK Panel Antibodies with Purified Antigens CD45, CD43, CD44 and CD18 and Three 'Novel' Antigens MEM-43, MEM-53 and MEM-102", pages 678-680. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7132395B1 (en) 1988-09-01 2006-11-07 Bayer Pharmaceuticals Corporation Antiviral methods using human rhinovirus receptor (ICAM-1)

Also Published As

Publication number Publication date
KR100206524B1 (ko) 1999-07-01
PT98326B (pt) 1999-01-29
AU8528691A (en) 1992-02-04
JP2001157592A (ja) 2001-06-12
AU658370B2 (en) 1995-04-13
JP2003038179A (ja) 2003-02-12
CA2087272C (fr) 2005-10-11
IE912466A1 (en) 1992-01-15
PT98326A (pt) 1992-06-30
WO1992001049A2 (fr) 1992-01-23
JPH06504186A (ja) 1994-05-19
CA2087272A1 (fr) 1992-01-14
EP0551301A1 (fr) 1993-07-21

Similar Documents

Publication Publication Date Title
WO1992001049A3 (fr) Antigene de surface de cellule cd53 et son utilisation
EP0330191A3 (fr) ADN encodant CD40
US4457867A (en) Physiologically active peptide
Sorace et al. Identification of an endotoxin and IFN‐inducible cDNA: possible identification of a novel protein family
US5702920A (en) DNAS encoding human macrophage migration inhibition factor related peptides
Walder et al. The organization and complete nucleotide sequence of the PstI restriction-modification system.
DK1000146T3 (da) 5' EST'er for non-vævsspecifikke secernerede proteiner
Higuchi et al. Human apolipoprotein B (apoB) mRNA: identification of two distinct apoB mRNAs, an mRNA with the apoB-100 sequence and an apoB mRNA containing a premature in-frame translational stop codon, in both liver and intestine.
WO1999006550A3 (fr) Marqueurs sequences 5' exprimes pour proteines secretees exprimees dans la prostate
IE66712B1 (en) Interleukin-1 inhibitors
WO1999006552A3 (fr) Est 5' pour proteines secretees exprimees dans le cerveau
CA2015077A1 (fr) Levure du genre schwanniomyces
WO1999006549B1 (fr) Est 5' pour proteines exprimees dans les testicules et autres tissus
CA2143491A1 (fr) Nouveau peptide lie a l'apoptose humaine et adn codant ledit peptide
CY1105398T1 (el) 5΄ ESTs ΓΙΑ ΕΚΚΡΙΤΙΚΕΣ ΠΡΩΤΕΪΝΕΣ ΠΟΥ ΕΚΦΡΑΖΟΝΤΑΙ ΣΕ ΔΙΑΦΟΡΟΥΣ ΙΣΤΟΥΣ
WO1999006551A3 (fr) Est 5' pour proteines secretees identifiees dans le tissu cerebral
WO1999006439A3 (fr) Est 5' pour proteines secretees exprimees dans l'endoderme
CA2020700A1 (fr) Composes pour l'inhibition de la formation d'une hormone proteinique et leurs utilisations
Bertolino et al. Cloning and characterization of a mouse type I hair keratin cDNA
Mattei et al. Localization of the gene for human erythrocyte glycophorin C to chromosome 2, q14–q21
ILAN et al. An mRNA bound initiation factor and its role in translation of natural message
JPH1017600A (ja) 血小板活性化因子アセチルヒドロラーゼおよびその遺伝子
US4935351A (en) Process for preparing oligopeptide
US5683696A (en) Cloning of duffy blood group antigen, gpD
DE69730814D1 (de) DAS NucA PROTEIN VON HAEMOPHILUS INFLUENZAE UND DESSEN KODIERENDER GEN

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2087272

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1991916292

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1991916292

Country of ref document: EP

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP KR

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

WWR Wipo information: refused in national office

Ref document number: 1991916292

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1991916292

Country of ref document: EP